GoAI
Get started
SI-BONE, Inc. logo

SI-BONE, Inc.

SIBN

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$19.96

+$0.48 · +2.46%

Aug 21, 4:00 PM ET

SIBN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

99

Deep Value

Momentum

58

Neutral

Sentiment

49

Mixed

Risk resilience

62

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Laura A. Francis
Listed since
Oct 17, 2018
Employees
376

Market position

Day range

Current $19.96

52-week range

Current $19.96

Open
$19.455
Previous close
$19.48
Volume
1.29M
2.08× average
Average volume
620.23K
Average daily volume
Market cap
885.21M USD
Beta
0.7
Market reference 1
50-day average
$17.4384
+14.46% above average
200-day average
$16.2695
+22.68% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
816.85M USD
P/E (TTM)
-58.74×
P/B (TTM)
4.84×
P/S (TTM)
4.14×
EV / EBITDA
-74.9×
Earnings yield
-2.20%
Free cash flow yield
-1.06%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
79.53%
Operating margin
-8.31%
Net margin
-6.85%
Return on equity
-10.65%
Return on assets
-7.93%
Return on invested capital
-10.42%

Financial health

Debt / equity
0.04×
Current ratio
8.55×
Altman Z-score
7.04
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends104%43%-17%-78%Gross margin, FY2021: 88.43%Gross margin, FY2022: 85.24%Gross margin, FY2023: 78.78%Gross margin, FY2024: 79.03%Gross margin, FY2025: 79.57%Operating margin, FY2021: -57.31%Operating margin, FY2022: -56.02%Operating margin, FY2023: -33.79%Operating margin, FY2024: -21.08%Operating margin, FY2025: -11.11%Net margin, FY2021: -62.75%Net margin, FY2022: -57.57%Net margin, FY2023: -31.20%Net margin, FY2024: -18.49%Net margin, FY2025: -9.41%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 88.43%. Gross margin FY2022 85.24%. Gross margin FY2023 78.78%. Gross margin FY2024 79.03%. Gross margin FY2025 79.57%. Operating margin FY2021 -57.31%. Operating margin FY2022 -56.02%. Operating margin FY2023 -33.79%. Operating margin FY2024 -21.08%. Operating margin FY2025 -11.11%. Net margin FY2021 -62.75%. Net margin FY2022 -57.57%. Net margin FY2023 -31.20%. Net margin FY2024 -18.49%. Net margin FY2025 -9.41%.

Income trends

Revenue

200.93M USD+20.19%

Operating income

−22.33M USD+36.65%

Net income

−18.91M USD+38.83%
Income trends across reported periods227.14M USD122.27M USD17.4M USD−87.47M USDRevenue, FY2021: 90.15M USDRevenue, FY2022: 106.41M USDRevenue, FY2023: 138.89M USDRevenue, FY2024: 167.18M USDRevenue, FY2025: 200.93M USDOperating income, FY2021: −51.67M USDOperating income, FY2022: −59.61M USDOperating income, FY2023: −46.93M USDOperating income, FY2024: −35.25M USDOperating income, FY2025: −22.33M USDNet income, FY2021: −56.57M USDNet income, FY2022: −61.26M USDNet income, FY2023: −43.34M USDNet income, FY2024: −30.91M USDNet income, FY2025: −18.91M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 90.15M USD. Revenue FY2022 106.41M USD. Revenue FY2023 138.89M USD. Revenue FY2024 167.18M USD. Revenue FY2025 200.93M USD. Operating income FY2021 −51.67M USD. Operating income FY2022 −59.61M USD. Operating income FY2023 −46.93M USD. Operating income FY2024 −35.25M USD. Operating income FY2025 −22.33M USD. Net income FY2021 −56.57M USD. Net income FY2022 −61.26M USD. Net income FY2023 −43.34M USD. Net income FY2024 −30.91M USD. Net income FY2025 −18.91M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue200.93M USD167.18M USD138.89M USD106.41M USD90.15M USD
Cost of goods sold41.05M USD35.06M USD29.47M USD15.71M USD10.43M USD
Gross profit159.88M USD132.12M USD109.42M USD90.7M USD79.72M USD
Research and development17.45M USD16.56M USD15.03M USD13.63M USD12.44M USD
Selling, general, and administrative164.76M USD150.81M USD141.32M USD136.69M USD118.95M USD
Operating expenses182.21M USD167.37M USD156.35M USD150.31M USD131.39M USD
Interest income6.07M USD7.85M USD6.92M USD1.3M USD186K USD
Interest expense5.28M USD3.44M USD3.46M USD2.82M USD5.37M USD
Depreciation and amortization2.72M USD4.38M USD5.43M USD3.45M USD2.09M USD
Operating income−22.33M USD−35.25M USD−46.93M USD−59.61M USD−51.67M USD
Net income−18.91M USD−30.91M USD−43.34M USD−61.26M USD−56.57M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-0.44
FY2025
Latest fiscal-year revenue
200.93M USD
FY2025 · +20.19% year over year
Next fiscal-year EPS consensus
-0.397
FY2026 · 6 analysts
Next fiscal-year revenue consensus
232.13M USD
FY2026 · 6 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.13-0.57-1.27-1.96FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend343.72M251.51M159.31M67.1MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$23.00

15.23% upside
Past 12 months12-month forecastHigh $25.00Average $23.00Low $21.00

Rating distribution

10 ratings
Strong buy00%
Buy10100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

9 institutions
UBSmaintainBuy
Canaccord GenuitymaintainBuy
Citizens Capital MarketsmaintainMarket Outperform

SIBN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SIBN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
23.75M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
21.87M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
8.14M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
7.88M
Weight
0.05%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
4.39M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
3.76M
Weight
0.02%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
iShares U.S. Medical Devices ETF logoiShares U.S. Medical Devices ETFIHI
Market value
3.66M
Weight
0.11%
AUM
3.49B USD
Expense ratio
0.37%
Price / 1D
$56.17+1.30%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
2.95M
Weight
0.20%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research SIBN

research.disclaimer